Stevioside
CAS 57817-89-7
Stevioside (CAS 57817-89-7) is a Phase 1 pharmaceutical compound with 0 bioactivity targets and 0 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| TAS2R4 TAS2R4 |
Agonist | 3.4700000286102295 pEC50 | 22616809 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| STEVIOSIDE | 37106 | SU | MTHSPL |
| stevioside | 37106 | IN | RXNORM |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Stevioside used for in pharmaceutical contexts?
Stevioside (CAS 57817-89-7) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Stevioside?
No adverse-event association or SIDER side-effect rows are rendered for Stevioside in this page query. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Stevioside also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for Stevioside with EU status "permitted".
What clinical phase is Stevioside in?
Stevioside is rendered with ChEMBL max phase 1.